LGG-43. CLINICAL EXPERIENCE OF BRAF AND MEK INHIBITOR THERAPY IN PAEDIATRIC GLIOMA

INTRODUCTION: MAPK pathway activation is a druggable target and characteristic of paediatric low-grade(pLGG) and also found in high-grade glioma(pHGG), typically resulting from BRAFV600E/BRAF-fusion/NF1 mutations. METHODS: A retrospective cohort study of 23 patients, who received BRAF inhibitor mono...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: O’Hare, Patricia, Loka, Thalia, D’Arco, Felice, Depani, Sarita, Michalski, Anthony, Slater, Olga, Jorgensen, Mette, Jacques, Thomas, Hargrave, Darren
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6012654/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy059.384
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados